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Purpose/Objective: This study proposed a method to estimate the 
beam-on time for prostate cancer patients treated on Tomotherapy 
when FW (field width), PF (pitch factor), modulation factor (MF) and 
treatment length (TL) were given. 
Materials and Methods: The study was divided into two parts: building 
and verifying the model. To build a model, 160 treatment plans were 
created for 10 patients. The plans differed in combination of FW, PF 
and MF. For all plans a graph of beam-on time as a function of TL was 
created and a linear trend function was fitted. Equation for each 
trend line was determined and used in a correlation model. Finally, 40 
plans verified the treatment time computation model - the real 
execution time was compared with our estimation and irradiation time 
calculated based on the equation provided by the manufacturer. 
Results: A linear trend function was drawn and the Pearson 
correlation coefficient r were calculated for each of the 8 trend lines 
corresponding to the adequate treatment plan. An equation to correct 
the model was determined to estimate more accurately the beam-on 
time for different MFs. Correlation was found to be high since for all 
plans r was higher than 0.98. The data showed that the estimation 
suggested by the manufacturer tended to underestimate the beam-on 
time on average by 52sec. However, differences of up to 154sec were 
observed. Whereas, the estimation based on the correlation model 
overestimated the treatment time on average by 14sec. In Figure 1B, 
an advantage of the correlation model might be observed, since the 
most frequent beam-on time differences were below 10% and the data 
were distributed almost symmetrically (skewness=– 0.08) which might 
suggest a good assessment of our model. 
 
  
Figure 1. Histogram of differences between real (from HT system) and 
estimated (from correlation model or manufacturer equation) beam-
on time in seconds (A) and percentage (B).  
 
Conclusions: Our study showed that the model can well predict the 
treatment time for a given TL, MF, FW and it can be used in clinical 
practice.  
   
EP-1213   
Commissioning and developing the use of 6MV flattening filter free 
L. Alder1, H. James1 
1The Ipswich Hospital NHS Trust, Radiotherapy Physics, Ipswich 
Suffolk, United Kingdom  
 
Purpose/Objective: To discuss key points identified during the 
commissioning of 6MV flattening filter free (FFF) and to identify 
treatment sites routinely treated using RapidArc© (Varian Medical 
Systems, Palo Alto) that could benefit from 6MVFFF. 
Materials and Methods: 6MVFFF was calibrated on the TrueBeam® 
linear accelerator (Varian Medical systems, Palo Alto) following the UK 
photon code of practice and the recommendations of Xiong et al 
(2008). Beam data was collected and the beam model configured in 
the Varian Eclipse TPS. The beam model was compared to measured 
data. Equipment routinely used for quality assurance, including the 
seven29 array (PTW, Freiburg), was tested in the high dose rate 
6MVFFF beam. To identify sites which may benefit from FFF a number 
of prostate and multi dose level head and neck patients were 
replanned using RapidArc© with 6MVFFF and 6MV flattened beams. All 
plans were optimised to produce clinically acceptable plans based on 
departmental protocols. For each plan the conformity index and 
homogeneity index were calculated and site specific organ doses were 
compared. 
Results: The 6MVFFF beam has been successfully calibrated with a 
correction of -0.5% being applied to kQ. The seven29 array with 
Octavius phantom can accurately measure dose at a dose rate of 
1400MU/min provided the measurement interval is adjusted to 200ms, 
but the QA BeamChecker™ Plus (Standard Imaging, United States) 
saturates at dose rates of 1400MU/min. However it is capable of 
accurately measuring at 1200MU/min.  
For standard prostate RapidArc treatments table one demonstrates 
there is no clinical benefit in using 6MVFFF over 6MV. All organs were 
within the departmental tolerances with no individual organ 
benefitting significantly from the FFF beam. For head and neck 
patients it seems there may be a benefit in using 6MVFFF. For organs 
further away from the PTV it is easier to meet the dose constraints 
and maximum doses in these organs are lower. This is due to the 
natural shape of the beam. For organs close to the PTV it is often 
possible to reduce the maximum dose as well.  
 
 
Conclusions: Further guidance on the calibration of these beams and 
possibly the development of a calibration procedure in FFF beams is 
necessary. Existing equipment can be successfully used in these high 
dose rate beams although it is sometimes necessary to limit the dose 
rate.  
Initial data suggests that FFF beams won’t benefit standard prostate 
treatments, but may help reduce the maximum dose to critical organs 
in head and neck treatments.  
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Purpose/Objective: Modern TPSs are coming with advanced dose 
calculation algorithms such as superposition. However, when using 
superposition algorithms it is more difficult to achieve ICRU 50 
recommendations (i.e. a minimum of 95% of the prescribed dose to 
the PTV) than with the old pencil beam convolution based algorithms 
due to the more accurate representation of the dose in heterogeneous 
media. The aim of this study was to determine the differences of dose 
calculations in lungs between two algorithms, and compare the 
calculations to measured doses. 
Materials and Methods: Semi-anthropomorphic phantom CIRS Thorax 
002 LFC was CT scanned and transferred to TPS. The phantom is 
elliptical in shape and represents an average human torso in 
proportion, density and two-dimensional structure. Plans were 
calculated according to IAEA TECDOC 1583 for verification of TPS, and 
measurements with ion chamber were conducted afterwards. Also, 
comparison of dose calculations for different clinical lung treatment 
plans were carried out for further 10 patients. Patient plans were 
calculated by both algorithms, but irradiated according to the results 
of the superposition algorithm. Also, old patient plans, clinically 
calculated and irradiated according to pencil beam calculations, were 
re-calculated by superposition, and differences evaluated. 
Results: The systematic dose overestimation by up to 15 % for the 
pencil beam convolution algorithm was recorded for all measurement 
points located inside the lung equivalent material. The range of 
